

Global Non-Opioid Pain Drug Market Growth (Status and Outlook) 2026-2032

<https://marketpublishers.com/r/G0417E8E456BEN.html>

Date: October 2026

Pages: 160

Price: US\$ 3,660.00 (Single User License)

ID: G0417E8E456BEN

Abstracts

The global Non-Opioid Pain Drug market size is predicted to grow from US\$ 41237 million in 2025 to US\$ 56903 million in 2032; it is expected to grow at a CAGR of 4.7% from 2026 to 2032.

Non-Opioid Pain Drug refers to pharmaceutical products that provide analgesic effects without relying on opioid receptor agonism as their primary pain-relief mechanism. The market covers a broad therapeutic spectrum ranging from established systemic analgesics to newer mechanism-specific and site-directed therapies, with major product categories including acetaminophen/paracetamol, nonsteroidal anti-inflammatory drugs (NSAIDs), selective COX-2 inhibitors, sodium channel pain signal inhibitors, local anesthetic analgesics, capsaicin-based analgesics, anticonvulsant analgesics, antidepressant analgesics and other non-opioid therapies. Products are commercialized as single-agent or combination drugs, across prescription and over-the-counter channels, and in oral, injectable, topical, transdermal and other formulations. The principal clinical applications include postoperative pain, musculoskeletal pain, arthritis pain, neuropathic pain, headache and migraine, dental pain, back pain, menstrual pain, injury and trauma pain, and selected cancer-related pain settings. The research focus therefore spans both high-volume routine pain management and differentiated prescription therapies designed for more targeted, prolonged or opioid-sparing analgesia.

Key Findings

The average gross profit margin of this product is 45%

NSAIDs and acetaminophen remain the broadest treatment foundation across pain care

Prescription innovation increasingly targets peripheral pain signaling without opioid receptor activation

Postoperative pain is a strategic field for long acting local analgesia

Oral drugs anchor routine use while topical formats widen treatment access

Competition spans consumer health specialty pharma and broad generic portfolios

Market Trends

The Non-Opioid Pain Drug market is moving from a structure dominated primarily by conventional systemic analgesics toward a more diversified treatment model combining established drugs, mechanism-targeted therapies, localized delivery and multimodal pain management. NSAIDs and acetaminophen continue to underpin routine acute and musculoskeletal pain treatment, while innovation is increasingly focused on improving analgesic selectivity, duration of action and site specificity. The U.S. FDA approval of suzetrigine in 2025 introduced a new class of oral non-opioid analgesia targeting peripheral sodium-channel-mediated pain signaling, illustrating the industry's growing interest in treating pain before signals reach central pathways. At the same time, prolonged local anesthetic formulations and dual-mechanism perioperative therapies are broadening the role of non-opioid drugs in postoperative pain management. Consumer pain-care products are also evolving through differentiated release profiles, topical formulations and fixed-dose combinations. The long-term direction of the market is therefore shifting from simply replacing opioids with conventional analgesics toward matching different pain mechanisms, treatment durations and clinical scenarios with more specialized non-opioid options.

Market Dynamics

Drivers

Demand for Non-Opioid Pain Drug products is supported by the persistent clinical burden of acute and chronic pain and by efforts to minimize unnecessary opioid exposure where effective alternatives are available. Non-opioid therapies already play an established role in common acute pain conditions, including musculoskeletal injuries, back pain and minor procedural pain, while acetaminophen, oral and topical NSAIDs and other non-opioid medicines remain widely integrated into routine treatment

pathways. Clinical practice is increasingly emphasizing treatment selection according to pain type, expected duration, patient risk factors and functional goals rather than relying on a single analgesic class. This creates a broad demand base covering both consumer self-care products and prescription therapies. Perioperative care represents an additional driver as hospitals and clinicians increasingly use multimodal analgesic strategies combining systemic medicines with long-acting or site-specific local therapies to improve pain control while reducing reliance on opioid rescue medication.

Restraints

The principal limitation of the Non-Opioid Pain Drug market is that non-opioid does not mean clinically unrestricted. Established drug classes have well-defined dosing, contraindication and tolerability considerations that limit their use in particular patient populations. NSAIDs, for example, are associated with gastrointestinal and cardiovascular risks that become particularly relevant in older patients, patients with underlying disease and prolonged treatment settings. Other therapeutic classes similarly require patient-specific assessment and may not provide adequate analgesia for every pain severity or mechanism. At the commercial level, many traditional non-opioid analgesics are mature and highly genericized, creating strong price competition and limiting differentiation for standard formulations. Conversely, newer proprietary therapies may face higher treatment costs, reimbursement scrutiny and formulary barriers. The market consequently operates between two pressures: commoditization in established drug classes and the need for newer therapies to demonstrate sufficient clinical and economic value to justify premium positioning.

Opportunities

The most important opportunity lies in expanding the therapeutic space between conventional first-line analgesics and opioid therapy. Mechanism-specific oral medicines, prolonged local anesthetics, topical and transdermal therapies and rational combination products provide multiple routes for companies to address this gap. Acute moderate-to-severe pain is becoming particularly important because successful non-opioid products can potentially participate in treatment settings historically associated with substantial opioid use. The emergence of peripheral sodium channel pain signal inhibition demonstrates the potential for fundamentally new analgesic mechanisms, while extended-duration local therapies create opportunities in surgery and procedure-related pain. Additional opportunities exist in neuropathic pain, musculoskeletal disorders and targeted topical treatment, where patient heterogeneity favors differentiated therapeutic approaches. Combination products also offer potential to

improve onset, duration or multimodal efficacy without relying on opioid components, supporting continued product reformulation and lifecycle innovation across both prescription and consumer-health markets.

Challenges

A central challenge for the Non-Opioid Pain Drug industry is translating pharmacological innovation into clinically meaningful advantages across highly heterogeneous pain conditions. Pain intensity is subjective, treatment response differs substantially among patients, and acute, inflammatory, neuropathic and postoperative pain involve different biological mechanisms. A therapy that performs well in one setting therefore cannot automatically establish broad value across the entire pain market. New prescription products must demonstrate not only statistically significant pain reduction but also clinically relevant improvements in duration, tolerability, functional recovery, opioid-sparing potential or ease of use. Companies must then secure reimbursement, hospital formulary access, physician adoption and patient acceptance while competing against inexpensive generic analgesics. Long development timelines and demanding clinical endpoints further increase commercialization risk. As the number of non-opioid approaches expands, differentiation will increasingly depend on clearly identifying the pain population, treatment setting and clinical value proposition in which each therapy provides a meaningful advantage.

Industry Chain Analysis

The upstream portion of the Non-Opioid Pain Drug industry consists primarily of active pharmaceutical ingredients, pharmaceutical intermediates, excipients and specialized formulation or drug-delivery materials. Conventional oral analgesics rely heavily on mature API manufacturing and large-scale solid-dose production, making manufacturing efficiency, quality control and supply security important competitive factors. More differentiated products introduce additional technical requirements, including sustained-release technologies, liposomal delivery systems, transdermal matrices, topical penetration systems and specialized injectable formulations. These technologies increase formulation complexity and can shift value creation away from the active ingredient alone toward proprietary delivery platforms, manufacturing know-how and intellectual property.

The midstream encompasses formulation development, clinical development, regulatory approval, commercial manufacturing, brand management and lifecycle management. Downstream channels differ significantly by product positioning: over-the-counter

analgesics depend heavily on pharmacies, retail and consumer-health distribution, while prescription products rely more strongly on hospitals, physicians, specialty pharmacy and institutional formularies. In postoperative applications, adoption is closely linked to surgical protocols and hospital pain-management pathways. The value chain is therefore bifurcated. Mature generic products derive competitive advantage from manufacturing scale, procurement efficiency and channel coverage, whereas innovative non-opioid therapies capture value through differentiated mechanisms, longer duration of action, targeted delivery, clinical evidence and intellectual-property protection.

Segment Insights

From a Type perspective, acetaminophen/paracetamol and NSAIDs represent the broadest foundation of the Non-Opioid Pain Drug market because of their established role across common acute, inflammatory, dental, musculoskeletal and self-treated pain. Selective COX-2 inhibitors occupy a more differentiated anti-inflammatory position, while local anesthetic analgesics have particular relevance in procedural and postoperative settings. Sodium channel pain signal inhibitors represent an emerging mechanism-oriented segment following the introduction of a first-in-class therapy for moderate-to-severe acute pain. Capsaicin-based products, anticonvulsant analgesics and antidepressant analgesics address more specialized pain mechanisms, particularly neuropathic and chronic pain conditions. The market is consequently becoming more segmented by pain biology rather than being defined only by analgesic strength.

Across Class, Group and Sort, single-agent drugs continue to provide the core treatment base, while combination products offer opportunities for complementary mechanisms and differentiated duration or onset of action. Prescription products are particularly important where pain severity, comorbidity or specialized delivery requires physician supervision, whereas OTC medicines remain central to everyday pain self-management. Oral formulations provide the widest routine-use platform, but injectable, topical and transdermal products allow treatment to become more site-specific and can address patients or clinical scenarios where systemic exposure is less desirable. The development of prolonged local analgesia and increasingly differentiated topical pain products suggests that formulation technology is becoming an important source of competitive separation alongside active pharmaceutical innovation.

Downstream Market Opportunities

Downstream demand for Non-Opioid Pain Drug products spans everyday self-treated pain and highly managed clinical pain pathways. Musculoskeletal pain, arthritis, back

pain, headache and migraine, dental pain and menstrual pain provide recurring demand for accessible oral and topical products, while neuropathic pain requires more mechanism-specific pharmacotherapy. Postoperative pain represents one of the most strategically important opportunities because treatment decisions occur within structured hospital and surgical protocols where duration of analgesia, recovery quality and opioid-sparing potential can materially influence product selection. Injury and trauma pain also support short-term acute treatment demand, while selected cancer-related pain settings create opportunities for non-opioid medicines as components of multimodal therapy. The major commercial opportunity is therefore not a single application, but the progressive segmentation of pain management according to etiology, severity, duration and treatment setting.

Regional Insights

North America is an important innovation and commercialization market for Non-Opioid Pain Drug products, particularly for novel prescription mechanisms and perioperative pain-management therapies. Recent regulatory progress in peripheral sodium channel inhibition and continued development of extended-duration local analgesics demonstrate active efforts to broaden non-opioid treatment options in acute and postoperative pain. The region also has a mature consumer-health market supported by established OTC analgesic brands. Europe similarly represents a mature market, with significant use of both prescription and OTC pain medicines and opportunities centered on formulation differentiation, localized pain treatment and improved patient selection.

Asia-Pacific combines a large base of conventional analgesic use with expanding demand for branded OTC products, prescription pain management and differentiated formulations. Japan has a well-developed topical and transdermal pain-treatment tradition, while China combines large-scale generic pharmaceutical manufacturing with increasing development of innovative and higher-value prescription therapies. Across emerging markets, affordability and broad distribution remain critical, meaning established oral drugs are likely to retain substantial importance even as more specialized products expand. Regional competition will therefore remain structurally different: innovation and premium prescription therapies are more prominent in developed markets, while manufacturing economics, accessibility and channel penetration remain especially influential in price-sensitive markets.

Competitive Landscape Analysis

The competitive landscape is structurally diversified rather than dominated by one type

of pharmaceutical company. Within the confirmed company set, Kenvue, Haleon and Bayer participate strongly through established consumer pain-care portfolios, while Vertex Pharmaceuticals Incorporated, Pfizer Inc., Pacira BioSciences, Inc., Heron Therapeutics, Inc., Scilex Holding Company and Gr?nenthal GmbH represent prescription or specialty-pharma approaches to differentiated pain management. Hisamitsu Pharmaceutical Co., Inc., Daiichi Sankyo Healthcare Co., Ltd. and AFT Pharmaceuticals Limited add regional and formulation-focused positions, while Viatrix Inc., Teva Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd. and Sun Pharmaceutical Industries Ltd. participate through broad pharmaceutical portfolios and large-scale manufacturing capabilities; Jiangsu Hengrui Pharmaceuticals Co., Ltd. represents the confirmed Chinese participant in the research scope. Competition therefore occurs across several dimensions simultaneously: consumer brand recognition, manufacturing scale, prescription access, formulation technology, proprietary mechanisms, clinical evidence and distribution reach. Recent progress in selective peripheral pain signaling and prolonged local analgesia indicates that future competitive differentiation is likely to rely increasingly on mechanism specificity and demonstrable clinical value rather than simple expansion of conventional analgesic portfolios.

Report Scope

LPI (LP Information)' newest research report, the "Non-Opioid Pain Drug Industry Forecast" looks at past sales and reviews total world Non-Opioid Pain Drug sales in 2025, providing a comprehensive analysis by region and market sector of projected Non-Opioid Pain Drug sales for 2026 through 2032. With Non-Opioid Pain Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Non-Opioid Pain Drug industry.

This Insight Report provides a comprehensive analysis of the global Non-Opioid Pain Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Non-Opioid Pain Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Non-Opioid Pain Drug market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Non-Opioid Pain Drug and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of

opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Non-Opioid Pain Drug.

This report presents a comprehensive overview, market shares, and growth opportunities of Non-Opioid Pain Drug market by product type, application, key players and key regions and countries.

Market Segmentation

Segmentation by Type:

Acetaminophen/Paracetamol

Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)

Selective COX-2 Inhibitors

Sodium Channel Pain Signal Inhibitors

Local Anesthetic Analgesics

Other

Segmentation by Drug Ingredients:

Single-Agent Drugs

Combination Drugs

Segmentation by Route of Administration:

Oral Drugs

Injectable Drugs

Topical Drugs

Segmentation by Application:

Postoperative Pain

Musculoskeletal Pain

Arthritis Pain

Neuropathic Pain

Headache and Migraine

Other

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

Vertex Pharmaceuticals

Kenvue

Haleon

Bayer

Pfizer

Pacira BioSciences

Heron Therapeutics

Scilex Holding

Gr?nenthal

Hisamitsu Pharmaceutical

Daiichi Sankyo

AFT Pharmaceuticals

Viatis

Teva Pharmaceutical

Dr. Reddy's

Sun Pharmaceutical

Jiangsu Hengrui

Johnson & Johnson

Hubei Hendi Pharmaceutical

CSPC Pharmaceutical Group

Sincere Pharmaceutical

Qilu Pharmaceutical

Yichang Humanwell Pharmaceutical

Tongfang Pharma

Fresenius

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

- 2.1 World Market Overview
 - 2.1.1 Global Non-Opioid Pain Drug Market Size (2021-2032)
 - 2.1.2 Non-Opioid Pain Drug Market Size CAGR by Region (2021 VS 2025 VS 2032)
 - 2.1.3 World Current & Future Analysis for Non-Opioid Pain Drug by Country/Region (2021, 2025 & 2032)
- 2.2 Non-Opioid Pain Drug Segment by Type
 - 2.2.1 Acetaminophen/Paracetamol
 - 2.2.2 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
 - 2.2.3 Selective COX-2 Inhibitors
 - 2.2.4 Sodium Channel Pain Signal Inhibitors
 - 2.2.5 Local Anesthetic Analgesics
 - 2.2.6 Other
 - 2.2.7 Non-Opioid Pain Drug Market Size by Type
 - 2.2.7.1 Non-Opioid Pain Drug Market Size CAGR by Type (2021 VS 2025 VS 2032)
 - 2.2.7.2 Global Non-Opioid Pain Drug Market Size Market Share by Type (2021-2026)
- 2.3 Non-Opioid Pain Drug Segment by Drug Ingredients
 - 2.3.1 Single-Agent Drugs
 - 2.3.2 Combination Drugs
 - 2.3.3 Non-Opioid Pain Drug Market Size by Drug Ingredients
 - 2.3.3.1 Non-Opioid Pain Drug Market Size CAGR by Drug Ingredients (2021 VS 2025 VS 2032)
 - 2.3.3.2 Global Non-Opioid Pain Drug Market Size Market Share by Drug Ingredients (2021-2026)
- 2.4 Non-Opioid Pain Drug Segment by Route of Administration

2.4.1 Oral Drugs

2.4.2 Injectable Drugs

2.4.3 Topical Drugs

2.4.4 Non-Opioid Pain Drug Market Size by Route of Administration

2.4.4.1 Non-Opioid Pain Drug Market Size CAGR by Route of Administration (2021 VS 2025 VS 2032)

2.4.4.2 Global Non-Opioid Pain Drug Market Size Market Share by Route of Administration (2021-2026)

2.5 Non-Opioid Pain Drug Segment by Application

2.5.1 Postoperative Pain

2.5.2 Musculoskeletal Pain

2.5.3 Arthritis Pain

2.5.4 Neuropathic Pain

2.5.5 Headache and Migraine

2.5.6 Other

2.5.7 Non-Opioid Pain Drug Market Size by Application

2.5.7.1 Non-Opioid Pain Drug Market Size CAGR by Application (2021 VS 2025 VS 2032)

2.5.7.2 Global Non-Opioid Pain Drug Market Size Market Share by Application (2021-2026)

3 NON-OPIOID PAIN DRUG MARKET SIZE BY PLAYER

3.1 Non-Opioid Pain Drug Market Size Market Share by Player

3.1.1 Global Non-Opioid Pain Drug Revenue by Player (2021-2026)

3.1.2 Global Non-Opioid Pain Drug Revenue Market Share by Player (2021-2026)

3.2 Global Non-Opioid Pain Drug Key Players Head office and Products Offered

3.3 Market Concentration Rate Analysis

3.3.1 Competition Landscape Analysis

3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

3.4 New Products and Potential Entrants

3.5 Mergers & Acquisitions, Expansion

4 NON-OPIOID PAIN DRUG BY REGION

4.1 Non-Opioid Pain Drug Market Size by Region (2021-2026)

4.2 Global Non-Opioid Pain Drug Annual Revenue by Country/Region (2021-2026)

4.3 Americas Non-Opioid Pain Drug Market Size Growth (2021-2026)

4.4 APAC Non-Opioid Pain Drug Market Size Growth (2021-2026)

4.5 Europe Non-Opioid Pain Drug Market Size Growth (2021-2026)

4.6 Middle East & Africa Non-Opioid Pain Drug Market Size Growth (2021-2026)

5 AMERICAS

5.1 Americas Non-Opioid Pain Drug Market Size by Country (2021-2026)

5.2 Americas Non-Opioid Pain Drug Market Size by Type (2021-2026)

5.3 Americas Non-Opioid Pain Drug Market Size by Application (2021-2026)

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC Non-Opioid Pain Drug Market Size by Region (2021-2026)

6.2 APAC Non-Opioid Pain Drug Market Size by Type (2021-2026)

6.3 APAC Non-Opioid Pain Drug Market Size by Application (2021-2026)

6.4 China

6.5 Japan

6.6 South Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

7 EUROPE

7.1 Europe Non-Opioid Pain Drug Market Size by Country (2021-2026)

7.2 Europe Non-Opioid Pain Drug Market Size by Type (2021-2026)

7.3 Europe Non-Opioid Pain Drug Market Size by Application (2021-2026)

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Non-Opioid Pain Drug by Region (2021-2026)

- 8.2 Middle East & Africa Non-Opioid Pain Drug Market Size by Type (2021-2026)
- 8.3 Middle East & Africa Non-Opioid Pain Drug Market Size by Application (2021-2026)
- 8.4 Egypt
- 8.5 South Africa
- 8.6 Israel
- 8.7 Turkey
- 8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

- 9.1 Market Drivers & Growth Opportunities
- 9.2 Market Challenges & Risks
- 9.3 Industry Trends

10 GLOBAL NON-OPIOID PAIN DRUG MARKET FORECAST

- 10.1 Global Non-Opioid Pain Drug Forecast by Region (2027-2032)
 - 10.1.1 Global Non-Opioid Pain Drug Forecast by Region (2027-2032)
 - 10.1.2 Americas Non-Opioid Pain Drug Forecast
 - 10.1.3 APAC Non-Opioid Pain Drug Forecast
 - 10.1.4 Europe Non-Opioid Pain Drug Forecast
 - 10.1.5 Middle East & Africa Non-Opioid Pain Drug Forecast
- 10.2 Americas Non-Opioid Pain Drug Forecast by Country (2027-2032)
 - 10.2.1 United States Market Non-Opioid Pain Drug Forecast
 - 10.2.2 Canada Market Non-Opioid Pain Drug Forecast
 - 10.2.3 Mexico Market Non-Opioid Pain Drug Forecast
 - 10.2.4 Brazil Market Non-Opioid Pain Drug Forecast
- 10.3 APAC Non-Opioid Pain Drug Forecast by Region (2027-2032)
 - 10.3.1 China Non-Opioid Pain Drug Market Forecast
 - 10.3.2 Japan Market Non-Opioid Pain Drug Forecast
 - 10.3.3 Korea Market Non-Opioid Pain Drug Forecast
 - 10.3.4 Southeast Asia Market Non-Opioid Pain Drug Forecast
 - 10.3.5 India Market Non-Opioid Pain Drug Forecast
 - 10.3.6 Australia Market Non-Opioid Pain Drug Forecast
- 10.4 Europe Non-Opioid Pain Drug Forecast by Country (2027-2032)
 - 10.4.1 Germany Market Non-Opioid Pain Drug Forecast
 - 10.4.2 France Market Non-Opioid Pain Drug Forecast
 - 10.4.3 UK Market Non-Opioid Pain Drug Forecast
 - 10.4.4 Italy Market Non-Opioid Pain Drug Forecast

- 10.4.5 Russia Market Non-Opioid Pain Drug Forecast
- 10.5 Middle East & Africa Non-Opioid Pain Drug Forecast by Region (2027-2032)
 - 10.5.1 Egypt Market Non-Opioid Pain Drug Forecast
 - 10.5.2 South Africa Market Non-Opioid Pain Drug Forecast
 - 10.5.3 Israel Market Non-Opioid Pain Drug Forecast
 - 10.5.4 Turkey Market Non-Opioid Pain Drug Forecast
- 10.6 Global Non-Opioid Pain Drug Forecast by Type (2027-2032)
- 10.7 Global Non-Opioid Pain Drug Forecast by Application (2027-2032)
 - 10.7.1 GCC Countries Market Non-Opioid Pain Drug Forecast

11 KEY PLAYERS ANALYSIS

- 11.1 Vertex Pharmaceuticals
 - 11.1.1 Vertex Pharmaceuticals Company Information
 - 11.1.2 Vertex Pharmaceuticals Non-Opioid Pain Drug Product Offered
 - 11.1.3 Vertex Pharmaceuticals Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026)
 - 11.1.4 Vertex Pharmaceuticals Main Business Overview
 - 11.1.5 Vertex Pharmaceuticals Latest Developments
- 11.2 Kenvue
 - 11.2.1 Kenvue Company Information
 - 11.2.2 Kenvue Non-Opioid Pain Drug Product Offered
 - 11.2.3 Kenvue Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026)
 - 11.2.4 Kenvue Main Business Overview
 - 11.2.5 Kenvue Latest Developments
- 11.3 Haleon
 - 11.3.1 Haleon Company Information
 - 11.3.2 Haleon Non-Opioid Pain Drug Product Offered
 - 11.3.3 Haleon Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026)
 - 11.3.4 Haleon Main Business Overview
 - 11.3.5 Haleon Latest Developments
- 11.4 Bayer
 - 11.4.1 Bayer Company Information
 - 11.4.2 Bayer Non-Opioid Pain Drug Product Offered
 - 11.4.3 Bayer Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026)
 - 11.4.4 Bayer Main Business Overview

- 11.4.5 Bayer Latest Developments
- 11.5 Pfizer
 - 11.5.1 Pfizer Company Information
 - 11.5.2 Pfizer Non-Opioid Pain Drug Product Offered
 - 11.5.3 Pfizer Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026)
 - 11.5.4 Pfizer Main Business Overview
 - 11.5.5 Pfizer Latest Developments
- 11.6 Pacira BioSciences
 - 11.6.1 Pacira BioSciences Company Information
 - 11.6.2 Pacira BioSciences Non-Opioid Pain Drug Product Offered
 - 11.6.3 Pacira BioSciences Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026)
 - 11.6.4 Pacira BioSciences Main Business Overview
 - 11.6.5 Pacira BioSciences Latest Developments
- 11.7 Heron Therapeutics
 - 11.7.1 Heron Therapeutics Company Information
 - 11.7.2 Heron Therapeutics Non-Opioid Pain Drug Product Offered
 - 11.7.3 Heron Therapeutics Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026)
 - 11.7.4 Heron Therapeutics Main Business Overview
 - 11.7.5 Heron Therapeutics Latest Developments
- 11.8 Scilex Holding
 - 11.8.1 Scilex Holding Company Information
 - 11.8.2 Scilex Holding Non-Opioid Pain Drug Product Offered
 - 11.8.3 Scilex Holding Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026)
 - 11.8.4 Scilex Holding Main Business Overview
 - 11.8.5 Scilex Holding Latest Developments
- 11.9 Gr?nenthal
 - 11.9.1 Gr?nenthal Company Information
 - 11.9.2 Gr?nenthal Non-Opioid Pain Drug Product Offered
 - 11.9.3 Gr?nenthal Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026)
 - 11.9.4 Gr?nenthal Main Business Overview
 - 11.9.5 Gr?nenthal Latest Developments
- 11.10 Hisamitsu Pharmaceutical
 - 11.10.1 Hisamitsu Pharmaceutical Company Information
 - 11.10.2 Hisamitsu Pharmaceutical Non-Opioid Pain Drug Product Offered

11.10.3 Hisamitsu Pharmaceutical Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026)

11.10.4 Hisamitsu Pharmaceutical Main Business Overview

11.10.5 Hisamitsu Pharmaceutical Latest Developments

11.11 Daiichi Sankyo

11.11.1 Daiichi Sankyo Company Information

11.11.2 Daiichi Sankyo Non-Opioid Pain Drug Product Offered

11.11.3 Daiichi Sankyo Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026)

11.11.4 Daiichi Sankyo Main Business Overview

11.11.5 Daiichi Sankyo Latest Developments

11.12 AFT Pharmaceuticals

11.12.1 AFT Pharmaceuticals Company Information

11.12.2 AFT Pharmaceuticals Non-Opioid Pain Drug Product Offered

11.12.3 AFT Pharmaceuticals Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026)

11.12.4 AFT Pharmaceuticals Main Business Overview

11.12.5 AFT Pharmaceuticals Latest Developments

11.13 Viatris

11.13.1 Viatris Company Information

11.13.2 Viatris Non-Opioid Pain Drug Product Offered

11.13.3 Viatris Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026)

11.13.4 Viatris Main Business Overview

11.13.5 Viatris Latest Developments

11.14 Teva Pharmaceutical

11.14.1 Teva Pharmaceutical Company Information

11.14.2 Teva Pharmaceutical Non-Opioid Pain Drug Product Offered

11.14.3 Teva Pharmaceutical Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026)

11.14.4 Teva Pharmaceutical Main Business Overview

11.14.5 Teva Pharmaceutical Latest Developments

11.15 Dr. Reddy's

11.15.1 Dr. Reddy's Company Information

11.15.2 Dr. Reddy's Non-Opioid Pain Drug Product Offered

11.15.3 Dr. Reddy's Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026)

11.15.4 Dr. Reddy's Main Business Overview

11.15.5 Dr. Reddy's Latest Developments

11.16 Sun Pharmaceutical

11.16.1 Sun Pharmaceutical Company Information

11.16.2 Sun Pharmaceutical Non-Opioid Pain Drug Product Offered

11.16.3 Sun Pharmaceutical Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026)

11.16.4 Sun Pharmaceutical Main Business Overview

11.16.5 Sun Pharmaceutical Latest Developments

11.17 Jiangsu Hengrui

11.17.1 Jiangsu Hengrui Company Information

11.17.2 Jiangsu Hengrui Non-Opioid Pain Drug Product Offered

11.17.3 Jiangsu Hengrui Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026)

11.17.4 Jiangsu Hengrui Main Business Overview

11.17.5 Jiangsu Hengrui Latest Developments

11.18 Johnson & Johnson

11.18.1 Johnson & Johnson Company Information

11.18.2 Johnson & Johnson Non-Opioid Pain Drug Product Offered

11.18.3 Johnson & Johnson Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026)

11.18.4 Johnson & Johnson Main Business Overview

11.18.5 Johnson & Johnson Latest Developments

11.19 Hubei Hendi Pharmaceutical

11.19.1 Hubei Hendi Pharmaceutical Company Information

11.19.2 Hubei Hendi Pharmaceutical Non-Opioid Pain Drug Product Offered

11.19.3 Hubei Hendi Pharmaceutical Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026)

11.19.4 Hubei Hendi Pharmaceutical Main Business Overview

11.19.5 Hubei Hendi Pharmaceutical Latest Developments

11.20 CSPC Pharmaceutical Group

11.20.1 CSPC Pharmaceutical Group Company Information

11.20.2 CSPC Pharmaceutical Group Non-Opioid Pain Drug Product Offered

11.20.3 CSPC Pharmaceutical Group Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026)

11.20.4 CSPC Pharmaceutical Group Main Business Overview

11.20.5 CSPC Pharmaceutical Group Latest Developments

11.21 Simcere Pharmaceutical

11.21.1 Simcere Pharmaceutical Company Information

11.21.2 Simcere Pharmaceutical Non-Opioid Pain Drug Product Offered

11.21.3 Simcere Pharmaceutical Non-Opioid Pain Drug Revenue, Gross Margin and

Market Share (2021-2026)

11.21.4 Simcere Pharmaceutical Main Business Overview

11.21.5 Simcere Pharmaceutical Latest Developments

11.22 Qilu Pharmaceutical

11.22.1 Qilu Pharmaceutical Company Information

11.22.2 Qilu Pharmaceutical Non-Opioid Pain Drug Product Offered

11.22.3 Qilu Pharmaceutical Non-Opioid Pain Drug Revenue, Gross Margin and

Market Share (2021-2026)

11.22.4 Qilu Pharmaceutical Main Business Overview

11.22.5 Qilu Pharmaceutical Latest Developments

11.23 Yichang Humanwell Pharmaceutical

11.23.1 Yichang Humanwell Pharmaceutical Company Information

11.23.2 Yichang Humanwell Pharmaceutical Non-Opioid Pain Drug Product Offered

11.23.3 Yichang Humanwell Pharmaceutical Non-Opioid Pain Drug Revenue, Gross

Margin and Market Share (2021-2026)

11.23.4 Yichang Humanwell Pharmaceutical Main Business Overview

11.23.5 Yichang Humanwell Pharmaceutical Latest Developments

11.24 Tongfang Pharma

11.24.1 Tongfang Pharma Company Information

11.24.2 Tongfang Pharma Non-Opioid Pain Drug Product Offered

11.24.3 Tongfang Pharma Non-Opioid Pain Drug Revenue, Gross Margin and Market

Share (2021-2026)

11.24.4 Tongfang Pharma Main Business Overview

11.24.5 Tongfang Pharma Latest Developments

11.25 Fresenius

11.25.1 Fresenius Company Information

11.25.2 Fresenius Non-Opioid Pain Drug Product Offered

11.25.3 Fresenius Non-Opioid Pain Drug Revenue, Gross Margin and Market Share

(2021-2026)

11.25.4 Fresenius Main Business Overview

11.25.5 Fresenius Latest Developments

12 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

- Table 1. Non-Opioid Pain Drug Market Size CAGR by Region (2021 VS 2025 VS 2032) & (\$ millions)
- Table 2. Non-Opioid Pain Drug Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & (\$ millions)
- Table 3. Major Players of Acetaminophen/Paracetamol
- Table 4. Major Players of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
- Table 5. Major Players of Selective COX-2 Inhibitors
- Table 6. Major Players of Sodium Channel Pain Signal Inhibitors
- Table 7. Major Players of Local Anesthetic Analgesics
- Table 8. Major Players of Other
- Table 9. Non-Opioid Pain Drug Market Size CAGR by Type (2021 VS 2025 VS 2032) & (\$ millions)
- Table 10. Global Non-Opioid Pain Drug Market Size by Type (2021-2026) & (\$ millions)
- Table 11. Global Non-Opioid Pain Drug Market Size Market Share by Type (2021-2026)
- Table 12. Major Players of Single-Agent Drugs
- Table 13. Major Players of Combination Drugs
- Table 14. Non-Opioid Pain Drug Market Size CAGR by Drug Ingredients (2021 VS 2025 VS 2032) & (\$ millions)
- Table 15. Global Non-Opioid Pain Drug Market Size by Drug Ingredients (2021-2026) & (\$ millions)
- Table 16. Global Non-Opioid Pain Drug Market Size Market Share by Drug Ingredients (2021-2026)
- Table 17. Major Players of Oral Drugs
- Table 18. Major Players of Injectable Drugs
- Table 19. Major Players of Topical Drugs
- Table 20. Non-Opioid Pain Drug Market Size CAGR by Route of Administration (2021 VS 2025 VS 2032) & (\$ millions)
- Table 21. Global Non-Opioid Pain Drug Market Size by Route of Administration (2021-2026) & (\$ millions)
- Table 22. Global Non-Opioid Pain Drug Market Size Market Share by Route of Administration (2021-2026)
- Table 23. Non-Opioid Pain Drug Market Size CAGR by Application (2021 VS 2025 VS 2032) & (\$ millions)
- Table 24. Global Non-Opioid Pain Drug Market Size by Application (2021-2026) & (\$ millions)

Table 25. Global Non-Opioid Pain Drug Market Size Market Share by Application (2021-2026)

Table 26. Global Non-Opioid Pain Drug Revenue by Player (2021-2026) & (\$ millions)

Table 27. Global Non-Opioid Pain Drug Revenue Market Share by Player (2021-2026)

Table 28. Non-Opioid Pain Drug Key Players Head office and Products Offered

Table 29. Non-Opioid Pain Drug Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

Table 30. New Products and Potential Entrants

Table 31. Mergers & Acquisitions, Expansion

Table 32. Global Non-Opioid Pain Drug Market Size by Region (2021-2026) & (\$ millions)

Table 33. Global Non-Opioid Pain Drug Market Size Market Share by Region (2021-2026)

Table 34. Global Non-Opioid Pain Drug Revenue by Country/Region (2021-2026) & (\$ millions)

Table 35. Global Non-Opioid Pain Drug Revenue Market Share by Country/Region (2021-2026)

Table 36. Americas Non-Opioid Pain Drug Market Size by Country (2021-2026) & (\$ millions)

Table 37. Americas Non-Opioid Pain Drug Market Size Market Share by Country (2021-2026)

Table 38. Americas Non-Opioid Pain Drug Market Size by Type (2021-2026) & (\$ millions)

Table 39. Americas Non-Opioid Pain Drug Market Size Market Share by Type (2021-2026)

Table 40. Americas Non-Opioid Pain Drug Market Size by Application (2021-2026) & (\$ millions)

Table 41. Americas Non-Opioid Pain Drug Market Size Market Share by Application (2021-2026)

Table 42. APAC Non-Opioid Pain Drug Market Size by Region (2021-2026) & (\$ millions)

Table 43. APAC Non-Opioid Pain Drug Market Size Market Share by Region (2021-2026)

Table 44. APAC Non-Opioid Pain Drug Market Size by Type (2021-2026) & (\$ millions)

Table 45. APAC Non-Opioid Pain Drug Market Size by Application (2021-2026) & (\$ millions)

Table 46. Europe Non-Opioid Pain Drug Market Size by Country (2021-2026) & (\$ millions)

Table 47. Europe Non-Opioid Pain Drug Market Size Market Share by Country

(2021-2026)

Table 48. Europe Non-Opioid Pain Drug Market Size by Type (2021-2026) & (\$ millions)

Table 49. Europe Non-Opioid Pain Drug Market Size by Application (2021-2026) & (\$ millions)

Table 50. Middle East & Africa Non-Opioid Pain Drug Market Size by Region (2021-2026) & (\$ millions)

Table 51. Middle East & Africa Non-Opioid Pain Drug Market Size by Type (2021-2026) & (\$ millions)

Table 52. Middle East & Africa Non-Opioid Pain Drug Market Size by Application (2021-2026) & (\$ millions)

Table 53. Key Market Drivers & Growth Opportunities of Non-Opioid Pain Drug

Table 54. Key Market Challenges & Risks of Non-Opioid Pain Drug

Table 55. Key Industry Trends of Non-Opioid Pain Drug

Table 56. Global Non-Opioid Pain Drug Market Size Forecast by Region (2027-2032) & (\$ millions)

Table 57. Global Non-Opioid Pain Drug Market Size Market Share Forecast by Region (2027-2032)

Table 58. Global Non-Opioid Pain Drug Market Size Forecast by Type (2027-2032) & (\$ millions)

Table 59. Global Non-Opioid Pain Drug Market Size Forecast by Application (2027-2032) & (\$ millions)

Table 60. Vertex Pharmaceuticals Details, Company Type, Non-Opioid Pain Drug Area Served and Its Competitors

Table 61. Vertex Pharmaceuticals Non-Opioid Pain Drug Product Offered

Table 62. Vertex Pharmaceuticals Non-Opioid Pain Drug Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 63. Vertex Pharmaceuticals Main Business

Table 64. Vertex Pharmaceuticals Latest Developments

Table 65. Kenvue Details, Company Type, Non-Opioid Pain Drug Area Served and Its Competitors

Table 66. Kenvue Non-Opioid Pain Drug Product Offered

Table 67. Kenvue Non-Opioid Pain Drug Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 68. Kenvue Main Business

Table 69. Kenvue Latest Developments

Table 70. Haleon Details, Company Type, Non-Opioid Pain Drug Area Served and Its Competitors

Table 71. Haleon Non-Opioid Pain Drug Product Offered

Table 72. Haleon Non-Opioid Pain Drug Revenue (\$ million), Gross Margin and Market

Share (2021-2026)

Table 73. Hialeon Main Business

Table 74. Hialeon Latest Developments

Table 75. Bayer Details, Company Type, Non-Opioid Pain Drug Area Served and Its Competitors

Table 76. Bayer Non-Opioid Pain Drug Product Offered

Table 77. Bayer Non-Opioid Pain Drug Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 78. Bayer Main Business

Table 79. Bayer Latest Developments

Table 80. Pfizer Details, Company Type, Non-Opioid Pain Drug Area Served and Its Competitors

Table 81. Pfizer Non-Opioid Pain Drug Product Offered

Table 82. Pfizer Non-Opioid Pain Drug Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 83. Pfizer Main Business

Table 84. Pfizer Latest Developments

Table 85. Pacira BioSciences Details, Company Type, Non-Opioid Pain Drug Area Served and Its Competitors

Table 86. Pacira BioSciences Non-Opioid Pain Drug Product Offered

Table 87. Pacira BioSciences Non-Opioid Pain Drug Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 88. Pacira BioSciences Main Business

Table 89. Pacira BioSciences Latest Developments

Table 90. Heron Therapeutics Details, Company Type, Non-Opioid Pain Drug Area Served and Its Competitors

Table 91. Heron Therapeutics Non-Opioid Pain Drug Product Offered

Table 92. Heron Therapeutics Non-Opioid Pain Drug Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 93. Heron Therapeutics Main Business

Table 94. Heron Therapeutics Latest Developments

Table 95. Scilex Holding Details, Company Type, Non-Opioid Pain Drug Area Served and Its Competitors

Table 96. Scilex Holding Non-Opioid Pain Drug Product Offered

Table 97. Scilex Holding Non-Opioid Pain Drug Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 98. Scilex Holding Main Business

Table 99. Scilex Holding Latest Developments

Table 100. Gr?nenthal Details, Company Type, Non-Opioid Pain Drug Area Served and

Its Competitors

Table 101. Gr?nenthal Non-Opioid Pain Drug Product Offered

Table 102. Gr?nenthal Non-Opioid Pain Drug Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 103. Gr?nenthal Main Business

Table 104. Gr?nenthal Latest Developments

Table 105. Hisamitsu Pharmaceutical Details, Company Type, Non-Opioid Pain Drug Area Served and Its Competitors

Table 106. Hisamitsu Pharmaceutical Non-Opioid Pain Drug Product Offered

Table 107. Hisamitsu Pharmaceutical Non-Opioid Pain Drug Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 108. Hisamitsu Pharmaceutical Main Business

Table 109. Hisamitsu Pharmaceutical Latest Developments

Table 110. Daiichi Sankyo Details, Company Type, Non-Opioid Pain Drug Area Served and Its Competitors

Table 111. Daiichi Sankyo Non-Opioid Pain Drug Product Offered

Table 112. Daiichi Sankyo Non-Opioid Pain Drug Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 113. Daiichi Sankyo Main Business

Table 114. Daiichi Sankyo Latest Developments

Table 115. AFT Pharmaceuticals Details, Company Type, Non-Opioid Pain Drug Area Served and Its Competitors

Table 116. AFT Pharmaceuticals Non-Opioid Pain Drug Product Offered

Table 117. AFT Pharmaceuticals Non-Opioid Pain Drug Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 118. AFT Pharmaceuticals Main Business

Table 119. AFT Pharmaceuticals Latest Developments

Table 120. Viatris Details, Company Type, Non-Opioid Pain Drug Area Served and Its Competitors

Table 121. Viatris Non-Opioid Pain Drug Product Offered

Table 122. Viatris Non-Opioid Pain Drug Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 123. Viatris Main Business

Table 124. Viatris Latest Developments

Table 125. Teva Pharmaceutical Details, Company Type, Non-Opioid Pain Drug Area Served and Its Competitors

Table 126. Teva Pharmaceutical Non-Opioid Pain Drug Product Offered

Table 127. Teva Pharmaceutical Non-Opioid Pain Drug Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 128. Teva Pharmaceutical Main Business

Table 129. Teva Pharmaceutical Latest Developments

Table 130. Dr. Reddy's Details, Company Type, Non-Opioid Pain Drug Area Served and Its Competitors

Table 131. Dr. Reddy's Non-Opioid Pain Drug Product Offered

Table 132. Dr. Reddy's Non-Opioid Pain Drug Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 133. Dr. Reddy's Main Business

Table 134. Dr. Reddy's Latest Developments

Table 135. Sun Pharmaceutical Details, Company Type, Non-Opioid Pain Drug Area Served and Its Competitors

Table 136. Sun Pharmaceutical Non-Opioid Pain Drug Product Offered

Table 137. Sun Pharmaceutical Non-Opioid Pain Drug Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 138. Sun Pharmaceutical Main Business

Table 139. Sun Pharmaceutical Latest Developments

Table 140. Jiangsu Hengrui Details, Company Type, Non-Opioid Pain Drug Area Served and Its Competitors

Table 141. Jiangsu Hengrui Non-Opioid Pain Drug Product Offered

Table 142. Jiangsu Hengrui Non-Opioid Pain Drug Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 143. Jiangsu Hengrui Main Business

Table 144. Jiangsu Hengrui Latest Developments

Table 145. Johnson & Johnson Details, Company Type, Non-Opioid Pain Drug Area Served and Its Competitors

Table 146. Johnson & Johnson Non-Opioid Pain Drug Product Offered

Table 147. Johnson & Johnson Non-Opioid Pain Drug Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 148. Johnson & Johnson Main Business

Table 149. Johnson & Johnson Latest Developments

Table 150. Hubei Hendi Pharmaceutical Details, Company Type, Non-Opioid Pain Drug Area Served and Its Competitors

Table 151. Hubei Hendi Pharmaceutical Non-Opioid Pain Drug Product Offered

Table 152. Hubei Hendi Pharmaceutical Non-Opioid Pain Drug Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 153. Hubei Hendi Pharmaceutical Main Business

Table 154. Hubei Hendi Pharmaceutical Latest Developments

Table 155. CSPC Pharmaceutical Group Details, Company Type, Non-Opioid Pain Drug Area Served and Its Competitors

Table 156. CSPC Pharmaceutical Group Non-Opioid Pain Drug Product Offered

Table 157. CSPC Pharmaceutical Group Non-Opioid Pain Drug Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 158. CSPC Pharmaceutical Group Main Business

Table 159. CSPC Pharmaceutical Group Latest Developments

Table 160. Simcere Pharmaceutical Details, Company Type, Non-Opioid Pain Drug Area Served and Its Competitors

Table 161. Simcere Pharmaceutical Non-Opioid Pain Drug Product Offered

Table 162. Simcere Pharmaceutical Non-Opioid Pain Drug Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 163. Simcere Pharmaceutical Main Business

Table 164. Simcere Pharmaceutical Latest Developments

Table 165. Qilu Pharmaceutical Details, Company Type, Non-Opioid Pain Drug Area Served and Its Competitors

Table 166. Qilu Pharmaceutical Non-Opioid Pain Drug Product Offered

Table 167. Qilu Pharmaceutical Non-Opioid Pain Drug Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 168. Qilu Pharmaceutical Main Business

Table 169. Qilu Pharmaceutical Latest Developments

Table 170. Yichang Humanwell Pharmaceutical Details, Company Type, Non-Opioid Pain Drug Area Served and Its Competitors

Table 171. Yichang Humanwell Pharmaceutical Non-Opioid Pain Drug Product Offered

Table 172. Yichang Humanwell Pharmaceutical Non-Opioid Pain Drug Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 173. Yichang Humanwell Pharmaceutical Main Business

Table 174. Yichang Humanwell Pharmaceutical Latest Developments

Table 175. Tongfang Pharma Details, Company Type, Non-Opioid Pain Drug Area Served and Its Competitors

Table 176. Tongfang Pharma Non-Opioid Pain Drug Product Offered

Table 177. Tongfang Pharma Non-Opioid Pain Drug Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 178. Tongfang Pharma Main Business

Table 179. Tongfang Pharma Latest Developments

Table 180. Fresenius Details, Company Type, Non-Opioid Pain Drug Area Served and Its Competitors

Table 181. Fresenius Non-Opioid Pain Drug Product Offered

Table 182. Fresenius Non-Opioid Pain Drug Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 183. Fresenius Main Business

Table 184. Fresenius Latest Developments

List Of Figures

LIST OF FIGURES

Figure 1. Non-Opioid Pain Drug Report Years Considered

Figure 2. Research Objectives

Figure 3. Research Methodology

Figure 4. Research Process and Data Source

Figure 5. Global Non-Opioid Pain Drug Market Size Growth Rate (2021-2032) (\$ millions)

Figure 6. Non-Opioid Pain Drug Sales by Geographic Region (2021, 2025 & 2032) & (\$ millions)

Figure 7. Non-Opioid Pain Drug Sales Market Share by Country/Region (2025)

Figure 8. Non-Opioid Pain Drug Sales Market Share by Country/Region (2021, 2025 & 2032)

Figure 9. Global Non-Opioid Pain Drug Market Size Market Share by Type in 2025

Figure 10. Global Non-Opioid Pain Drug Market Size Market Share by Drug Ingredients in 2025

Figure 11. Global Non-Opioid Pain Drug Market Size Market Share by Route of Administration in 2025

Figure 12. Non-Opioid Pain Drug in Postoperative Pain

Figure 13. Global Non-Opioid Pain Drug Market: Postoperative Pain (2021-2026) & (\$ millions)

Figure 14. Non-Opioid Pain Drug in Musculoskeletal Pain

Figure 15. Global Non-Opioid Pain Drug Market: Musculoskeletal Pain (2021-2026) & (\$ millions)

Figure 16. Non-Opioid Pain Drug in Arthritis Pain

Figure 17. Global Non-Opioid Pain Drug Market: Arthritis Pain (2021-2026) & (\$ millions)

Figure 18. Non-Opioid Pain Drug in Neuropathic Pain

Figure 19. Global Non-Opioid Pain Drug Market: Neuropathic Pain (2021-2026) & (\$ millions)

Figure 20. Non-Opioid Pain Drug in Headache and Migraine

Figure 21. Global Non-Opioid Pain Drug Market: Headache and Migraine (2021-2026) & (\$ millions)

Figure 22. Non-Opioid Pain Drug in Other

Figure 23. Global Non-Opioid Pain Drug Market: Other (2021-2026) & (\$ millions)

Figure 24. Global Non-Opioid Pain Drug Market Size Market Share by Application in 2025

Figure 25. Global Non-Opioid Pain Drug Revenue Market Share by Player in 2025

Figure 26. Global Non-Opioid Pain Drug Market Size Market Share by Region (2021-2026)

Figure 27. Americas Non-Opioid Pain Drug Market Size 2021-2026 (\$ millions)

Figure 28. APAC Non-Opioid Pain Drug Market Size 2021-2026 (\$ millions)

Figure 29. Europe Non-Opioid Pain Drug Market Size 2021-2026 (\$ millions)

Figure 30. Middle East & Africa Non-Opioid Pain Drug Market Size 2021-2026 (\$ millions)

Figure 31. Americas Non-Opioid Pain Drug Value Market Share by Country in 2025

Figure 32. United States Non-Opioid Pain Drug Market Size Growth 2021-2026 (\$ millions)

Figure 33. Canada Non-Opioid Pain Drug Market Size Growth 2021-2026 (\$ millions)

Figure 34. Mexico Non-Opioid Pain Drug Market Size Growth 2021-2026 (\$ millions)

Figure 35. Brazil Non-Opioid Pain Drug Market Size Growth 2021-2026 (\$ millions)

Figure 36. APAC Non-Opioid Pain Drug Market Size Market Share by Region in 2025

Figure 37. APAC Non-Opioid Pain Drug Market Size Market Share by Type (2021-2026)

Figure 38. APAC Non-Opioid Pain Drug Market Size Market Share by Application (2021-2026)

Figure 39. China Non-Opioid Pain Drug Market Size Growth 2021-2026 (\$ millions)

Figure 40. Japan Non-Opioid Pain Drug Market Size Growth 2021-2026 (\$ millions)

Figure 41. South Korea Non-Opioid Pain Drug Market Size Growth 2021-2026 (\$ millions)

Figure 42. Southeast Asia Non-Opioid Pain Drug Market Size Growth 2021-2026 (\$ millions)

Figure 43. India Non-Opioid Pain Drug Market Size Growth 2021-2026 (\$ millions)

Figure 44. Australia Non-Opioid Pain Drug Market Size Growth 2021-2026 (\$ millions)

Figure 45. Europe Non-Opioid Pain Drug Market Size Market Share by Country in 2025

Figure 46. Europe Non-Opioid Pain Drug Market Size Market Share by Type (2021-2026)

Figure 47. Europe Non-Opioid Pain Drug Market Size Market Share by Application (2021-2026)

Figure 48. Germany Non-Opioid Pain Drug Market Size Growth 2021-2026 (\$ millions)

Figure 49. France Non-Opioid Pain Drug Market Size Growth 2021-2026 (\$ millions)

Figure 50. UK Non-Opioid Pain Drug Market Size Growth 2021-2026 (\$ millions)

Figure 51. Italy Non-Opioid Pain Drug Market Size Growth 2021-2026 (\$ millions)

Figure 52. Russia Non-Opioid Pain Drug Market Size Growth 2021-2026 (\$ millions)

Figure 53. Middle East & Africa Non-Opioid Pain Drug Market Size Market Share by Region (2021-2026)

Figure 54. Middle East & Africa Non-Opioid Pain Drug Market Size Market Share by

Type (2021-2026)

Figure 55. Middle East & Africa Non-Opioid Pain Drug Market Size Market Share by Application (2021-2026)

Figure 56. Egypt Non-Opioid Pain Drug Market Size Growth 2021-2026 (\$ millions)

Figure 57. South Africa Non-Opioid Pain Drug Market Size Growth 2021-2026 (\$ millions)

Figure 58. Israel Non-Opioid Pain Drug Market Size Growth 2021-2026 (\$ millions)

Figure 59. Turkey Non-Opioid Pain Drug Market Size Growth 2021-2026 (\$ millions)

Figure 60. GCC Countries Non-Opioid Pain Drug Market Size Growth 2021-2026 (\$ millions)

Figure 61. Americas Non-Opioid Pain Drug Market Size 2027-2032 (\$ millions)

Figure 62. APAC Non-Opioid Pain Drug Market Size 2027-2032 (\$ millions)

Figure 63. Europe Non-Opioid Pain Drug Market Size 2027-2032 (\$ millions)

Figure 64. Middle East & Africa Non-Opioid Pain Drug Market Size 2027-2032 (\$ millions)

Figure 65. United States Non-Opioid Pain Drug Market Size 2027-2032 (\$ millions)

Figure 66. Canada Non-Opioid Pain Drug Market Size 2027-2032 (\$ millions)

Figure 67. Mexico Non-Opioid Pain Drug Market Size 2027-2032 (\$ millions)

Figure 68. Brazil Non-Opioid Pain Drug Market Size 2027-2032 (\$ millions)

Figure 69. China Non-Opioid Pain Drug Market Size 2027-2032 (\$ millions)

Figure 70. Japan Non-Opioid Pain Drug Market Size 2027-2032 (\$ millions)

Figure 71. Korea Non-Opioid Pain Drug Market Size 2027-2032 (\$ millions)

Figure 72. Southeast Asia Non-Opioid Pain Drug Market Size 2027-2032 (\$ millions)

Figure 73. India Non-Opioid Pain Drug Market Size 2027-2032 (\$ millions)

Figure 74. Australia Non-Opioid Pain Drug Market Size 2027-2032 (\$ millions)

Figure 75. Germany Non-Opioid Pain Drug Market Size 2027-2032 (\$ millions)

Figure 76. France Non-Opioid Pain Drug Market Size 2027-2032 (\$ millions)

Figure 77. UK Non-Opioid Pain Drug Market Size 2027-2032 (\$ millions)

Figure 78. Italy Non-Opioid Pain Drug Market Size 2027-2032 (\$ millions)

Figure 79. Russia Non-Opioid Pain Drug Market Size 2027-2032 (\$ millions)

Figure 80. Egypt Non-Opioid Pain Drug Market Size 2027-2032 (\$ millions)

Figure 81. South Africa Non-Opioid Pain Drug Market Size 2027-2032 (\$ millions)

Figure 82. Israel Non-Opioid Pain Drug Market Size 2027-2032 (\$ millions)

Figure 83. Turkey Non-Opioid Pain Drug Market Size 2027-2032 (\$ millions)

Figure 84. Global Non-Opioid Pain Drug Market Size Market Share Forecast by Type (2027-2032)

Figure 85. Global Non-Opioid Pain Drug Market Size Market Share Forecast by Application (2027-2032)

Figure 86. GCC Countries Non-Opioid Pain Drug Market Size 2027-2032 (\$ millions)

I would like to order

Product name: Global Non-Opioid Pain Drug Market Growth (Status and Outlook) 2026-2032

Product link: <https://marketpublishers.com/r/G0417E8E456BEN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G0417E8E456BEN.html>